KYORIN Holdings, Inc. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2016; Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2016
July 29, 2016
Share
KYORIN Holdings, Inc. announced consolidated earnings results for the first quarter ended June 30, 2016. For the quarter, the company reported net sales of JPY 27,707 million compared with JPY 26,567 million a year ago. Operating income was JPY 3,244 million compared with JPY 2,173 million a year ago. Ordinary income was JPY 3,485 million compared with JPY 2,316 million a year ago. Net income was JPY 2,580 million or JPY 35.15 per share compared with JPY 1,757 million or JPY 23.76 per share a year ago.
For the first half of fiscal year ending March 31, 2017, on consolidated basis, the company expects net sales of JPY 53,900 million, operating income of JPY 3,900 million, ordinary income of JPY 4,200 million and profit attributable to owners of parent of JPY 3,600 million or JPY 40.72 per share.
For the full year ending March 31, 2017, on consolidated basis, the company expects net sales of JPY 120,000 million, operating income of JPY 14,500 million, ordinary income of JPY 14,900 million and profit attributable to owners of parent of JPY 10,700 million or JPY 145.23 per share.
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.
KYORIN Holdings, Inc. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2016; Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2016